14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:KITE
Delisted

Kite Pharma Fund Price (Quote)

NASDAQ Stock Exchange
Open Broker Account
$179.79
+0 (+0%)
At Close: Oct 19, 2017
Forecast Signals Historical Prices Predictions Profile

Range Low Price High Price Comment
30 days $178.86 $179.95 Thursday, 19th Oct 2017 KITE stock ended at $179.79. During the day the stock fluctuated 0% from a day low at $179.79 to a day high of $179.79.
90 days $105.61 $179.95
52 weeks $39.82 $179.95

Historical Kite Pharma prices

Date Open High Low Close Volume
Oct 19, 2017 $179.79 $179.79 $179.79 $179.79 0
Oct 18, 2017 $179.79 $179.79 $179.79 $179.79 0
Oct 17, 2017 $179.79 $179.79 $179.79 $179.79 0
Oct 16, 2017 $179.79 $179.79 $179.79 $179.79 0
Oct 13, 2017 $179.79 $179.79 $179.79 $179.79 0
Oct 12, 2017 $179.82 $179.95 $179.55 $179.79 100
Oct 11, 2017 $179.82 $179.95 $179.55 $179.79 100
Oct 10, 2017 $179.82 $179.95 $179.55 $179.79 100
Oct 09, 2017 $179.82 $179.95 $179.55 $179.79 100
Oct 06, 2017 $179.82 $179.95 $179.55 $179.79 100
Oct 05, 2017 $179.82 $179.95 $179.55 $179.79 100
Oct 04, 2017 $179.82 $179.95 $179.55 $179.79 100
Oct 03, 2017 $179.82 $179.95 $179.55 $179.79 100
Oct 02, 2017 $179.82 $179.95 $179.55 $179.79 3 747 321
Sep 29, 2017 $179.75 $179.87 $179.73 $179.81 1 580 860
Sep 28, 2017 $179.72 $179.78 $179.67 $179.73 1 112 341
Sep 27, 2017 $179.74 $179.74 $179.61 $179.68 1 447 172
Sep 26, 2017 $179.80 $179.84 $179.52 $179.64 3 587 548
Sep 25, 2017 $179.20 $179.52 $179.20 $179.40 2 060 394
Sep 22, 2017 $179.40 $179.44 $179.06 $179.30 1 799 798
Sep 21, 2017 $179.50 $179.62 $179.22 $179.38 1 853 395
Sep 20, 2017 $179.41 $179.79 $179.25 $179.74 1 482 844
Sep 19, 2017 $178.86 $179.51 $178.86 $179.50 1 795 995
Sep 18, 2017 $178.76 $179.16 $178.76 $178.89 2 111 103
Sep 15, 2017 $178.99 $179.48 $178.60 $178.61 3 194 488
Click to get the best stock tips daily for free!

About Kite Pharma

Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a chimeric antigen receptors (CAR)-based therapy that is in Phase 2 clinical trials for the treatmen... KITE Profile

Golden Star

Ticker Date Change Price
HRB Apr 29 1.00% $47.23
LYG Apr 29 0.391% $2.56
ORA Apr 29 1.95% $64.48
ETSY Apr 26 3.43% $67.43
DHT Apr 24 0.98% $11.28
LPLA Apr 19 1.10% $262.59
MLI Apr 19 7.29% $52.28
PFLT Apr 18 1.33% $11.25
DOOR Apr 18 0.94% $131.39
OCSL Apr 17 0.360% $19.43
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT